Meloxicam Tablet
Product Images NDC 76282-152

This is a label of Meloxicam tablets, a medication used for pain relief and reduction of inflammation. The tablets are 7.5 mg and are packaged in a bottle containing 1000 tablets. The label reminds users to consult a pharmacist or doctor to determine the appropriate dosage and to keep the medication out of the reach of children. Additionally, there are dosage instructions and contact details for the manufacturer.*

This is a description of Meloxicam Tablets USP, a prescription only medication manufactured by Ascent Pharmaceutical, Inc. The medication guide should accompany the dispensing by a pharmacist. The dosage instructions are provided with the prescription information. The drug should be kept in an airtight container, in a cool place, out of the reach of children. The manufacturer is Exelan Pharmaceutical, headquartered in Lawrenceville, GA.*

This document presents tables indicating adverse events with meloxicam, a nonsteroidal anti-inflammatory drug, in patients with osteoarthritis and rheumatoid arthritis. The tables show the percentage of patients experiencing different adverse events for varying doses and treatment durations of meloxicam, compared to those taking placebo or other drugs as a control. Adverse events were mostly gastrointestinal, but there were also events related to the nervous, respiratory, musculoskeletal, and urinary systems, as well as rashes and edemas.*

This appears to be a list of different reactions, symptoms, and conditions related to various bodily systems, such as the cardiovascular system, nervous system, gastrointestinal system, and metabolic system, among others. The list includes both positive and negative reactions that can occur, such as weight increase or decrease, allergic reactions, hypertension or hypotension, as well as more serious conditions such as myocardial infarction or intestinal perforation. It is not clear what this list is for or where it comes from.*

The text provides information on the clinical impact and interventions related to various drugs that interfere with hemostasis, including Meloxicam and anticoagulants, aspirin, ACE inhibitors, angiotensin receptor blockers, or beta-blockers, diuretics, lithium, Methotrexate, cyclosporine, NSAIDs, and salicylates. Concomitant use of these drugs may increase the risk of bleeding, hypertension, renal dysfunction, and toxicity. Healthcare professionals should monitor patients' blood pressure, renal function, and signs of bleeding or toxicity, as well as ensure that patients are adequately hydrated. They should also interrupt dosing before and after administering pemetrexed to avoid myelosuppression, renal, and GI toxicity.*

Table 4 presents the pharmacokinetic parameters for oral meloxicam of 7.5 mg and 15 mg at single dose and steady-state. The table includes data for healthy young adults, elderly males and females, and for those with renal or hepatic insufficiency. The mean values and percentage of oral bioavailability are given for each group of individuals studied. Some information on the dosage forms tested is also provided. The information comes from multiple studies, but the conditions of high-fat intake were not tested.*